Molluscum contagiosum virus cDNA and Antigen

Molluscum contagiosum virus (MCV) is a common skin virus that infects humans. There are two subtypes of MCV, each with a major envelope protein called p43K. MCV subtype 1 and subtype 2 are highly similar in terms of genetic structure and clinical presentation but can be differentiated based on differences in their major envelope proteins.

The major envelope protein p43K plays a crucial role in the attachment and entry of the virus into host cells. It is also important for the assembly of the virus particles and their release from infected cells. MCV infection is generally benign and self-limiting but can cause persistent skin lesions in immunocompromised individuals. Treatment options for MCV infection include physical removal of the lesions and antiviral therapy.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E.coli expression Vector), which are ready for production of the recombinant proteins.